Sign in
Taking peopleNo phase

Prognostic Analysis of Different Treatment Options for Cerebral Hemorrhage

Key facts

Who runs it
The Affiliated Hospital Of Guizhou Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
1,000 people, planned
Started
1 Jan 2014
Expected to end
31 Jan 2028
Type of study
Observational, 4 groups
Treatments tested
  • Stereotactic intracranial hematoma puncture
  • decompressive craniectomy
  • Neuroendoscopic
Record updated
18 March 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age 18-80 years old
  • Intracerebral hemorrhage was diagnosed by head CT examination

Who cannot take part

  • Multiple intracranial hemorrhage
  • Intracranial hemorrhage caused by intracranial tumor, aneurysm, trauma, infarction or other lesions
  • Coagulation disorders or a history of taking anticoagulants
  • Infectious meningitis, systemic infection
  • History of severe stroke, heart, kidney, liver and lung dysfunction in the past
  • Severe brain herniation (mydriasis, respiratory and circulatory failure)
  • Incomplete or missing basic data or follow-up information in the hospital

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To analyze the influence of early hematoma morphology on hematoma expansion, optimize the treatment plan for cerebral hemorrhage, and guide the treatment of patients with cerebral hemorrhage in combination with clinical practice.

The 4 groups in the trial

  • Stereotactic intracranial hematoma puncture treatment group

    Check the CT slice of the patient's brain, find out the patient's largest hematoma level, measure the coordinates of the puncture center, locate and mark the skull surface according to the measured coordinates, select the puncture point under the stereotaxic instrument, Mainly avoid important blood vessels, nerves and functional areas. Use an electric drill to drill the puncture needle into the center of the hematoma, and slowly aspirate the hematoma from the side hole until the suction stops when there is resistance. The residual hematoma in CT and the location of the drainage tube were determined, and the position of the puncture needle was adjusted for the situation of brain CT. After the operation, according to the re-examination of cranial CT, urokinase was injected into the hematoma cavity through the drainage tube to dissolve the residual hematoma, and the operation process strictly followed aseptic operation.

    Treatment: Stereotactic intracranial hematoma puncture

  • drug treatment group

    General treatment: Based on high-level nursing care and close and continuous attention to the patient's vital signs, the patient is instructed to stay in bed continuously, give oxygen, and instruct the patient to avoid emotional agitation, etc. ②Special treatment: use hemostatic drugs, control blood pressure to prevent rebleeding, control blood sugar, control body temperature, anti-epilepsy, prevent infection, dehydration and lower intracranial pressure, etc. Multisystem complications such as tract hemorrhage should be actively managed.

  • decompressive craniectomy treatment group

    Prior to the procedure, all patients obtained endotracheal intubation under general anesthesia following the informed consent provided by their family members. Upon identifying the hematoma's location through CT imaging, the surgeon made a linear or horseshoe-shaped incision on the scalp and subsequently opened the dura mater after creating a bone flap. The hematoma was punctured using a brain needle, allowing for effective decompression. The cerebral cortex was incised along the cerebral gyri, facilitating the separation of brain tissue to eliminate residual hematoma. Once hemostasis was ensured within the operative area, a silicone drainage tube was inserted, and the cranial bone flap was restored to its original position. In cases of severe brain edema or cerebral herniation, bone flap decompression was performed.

    Treatment: decompressive craniectomy

  • Neuroendoscopic treatment group

    The patient's preoperative CT and MR imaging data were fused with a neuronavigation system to avoid important functional areas and select the closest point of the hematoma to the cortex as the location point. Routine craniotomy was performed with a 2\*3 cm bone window, the puncture direction was repositioned by neuronavigation, the sheath was placed at the center of the hematoma, the core was removed, the endoscope was gradually aspirated, and the bleeding was stopped with electrocoagulation if there was considerable active bleeding. A drainage tube was placed, the bone flap was reset after surgery, and the scalp was sutured.

    Treatment: Neuroendoscopic

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Analysis of Related Factors of Hematoma Morphology in Patients With Cerebral Hemorrhage and Prognosis Analysis of Different Regimens for Cerebral Hemorrhage
Criteria questions
Built from NCT05548530, who can take part
Publications
Record updated
18 March 2026